百例之约 | 新辅助免疫联合化疗为中晚期肺鳞癌患者带来惊喜!患者术后实现pCR( 三 )
[3] Zhang T, et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67(7):1079-1090.
[4] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial[J]. Lancet, 2016, 79(3): 1540-1550.
推荐阅读
- 新辅助免疫治疗发展如何?腔镜肺段切除有哪些技巧?这个大会将这些肺癌热点一网打尽
- 南昌大学第二附属医院消化内科2020年TIPS首破百例再创新高
- 新辅助化疗易导致耐药,癌症患者该如何选择?
- 红海之约,视觉盛宴,肖战王一博杨紫罗云熙加入星光大赏盛典
- 宝鸡市首家运动医学科开诊三个月手术近百例
- 茅善玉和宁波有个神秘的“十年之约”
- 扶手倚红楼|60岁之约!身家上亿何家劲没实现娶高金素梅诺言